Eli Lilly and Company $LLY Shares Sold by Sirios Capital Management L P

Sirios Capital Management L P cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 16.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 12,297 shares of the company’s stock after selling 2,378 shares during the quarter. Eli Lilly and Company comprises about 1.4% of Sirios Capital Management L P’s investment portfolio, making the stock its 25th largest position. Sirios Capital Management L P’s holdings in Eli Lilly and Company were worth $9,586,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC boosted its stake in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares in the last quarter. Kaufman Rossin Wealth LLC purchased a new stake in Eli Lilly and Company during the first quarter worth $242,000. Sustainable Insight Capital Management LLC grew its holdings in Eli Lilly and Company by 10.6% in the first quarter. Sustainable Insight Capital Management LLC now owns 9,367 shares of the company’s stock valued at $7,736,000 after purchasing an additional 900 shares during the last quarter. Finally, Core Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 18.2% in the first quarter. Core Wealth Partners LLC now owns 915 shares of the company’s stock valued at $756,000 after buying an additional 141 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on LLY shares. Weiss Ratings raised shares of Eli Lilly and Company from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, December 3rd. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Sanford C. Bernstein upped their target price on Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the company an “outperform” rating in a research note on Monday, November 24th. National Bankshares set a $1,286.00 price target on Eli Lilly and Company in a research report on Monday, December 1st. Finally, Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,091.62.

Eli Lilly and Company Trading Down 1.6%

NYSE LLY opened at $981.89 on Wednesday. The company has a market cap of $928.26 billion, a P/E ratio of 48.04, a P/E/G ratio of 1.11 and a beta of 0.37. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The company has a 50-day moving average of $928.62 and a 200-day moving average of $814.21.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is currently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.